Scientific deep-dive
Uric Acid and Two Answers
Two studies asked whether these drugs lower uric acid. Both said yes. One found the effect 72.7% explained by weight loss; the other found it independent of weight loss.
Two studies asked whether these drugs lower uric acid. Both said yes. One found the effect was 72.7% explained by weight loss; the other found it was independent of weight loss.[1][2] They also disagree about the size of the effect by a factor of five, and a reader who met either one alone would come away confident about something the other contradicts.
Why uric acid matters here
Uric acid is the substance that crystallizes in joints to cause gout, and gout is disproportionately common in people carrying excess weight. Treatment is managed to a target: bring serum urate below 6.0 mg/dL and crystals dissolve rather than form.
Because of that threshold, the size of any reduction is what matters. A fall of a full milligram per deciliter can carry someone across the line. A fall of two-tenths cannot.
The randomized answer
A post hoc analysis of SURMOUNT-1 tracked serum urate in 2,539 adults with obesity or overweight across 72 weeks of tirzepatide or placebo.[1]
| Arm | Change in serum urate |
|---|---|
| Tirzepatide 5 mg | −0.69 mg/dL |
| Tirzepatide 10 mg | −0.92 mg/dL |
| Tirzepatide 15 mg | −0.95 mg/dL |
| Placebo | −0.18 mg/dL |
All active doses beat placebo at P<.001, and the reduction held regardless of where someone started: it did not matter which quartile of baseline urate they were in (P = .610) or what their BMI was (P = .362). Mediation analysis then attributed 72.7% of the urate reduction to the weight loss itself.
The real-world answer
URISEMA looked retrospectively at 236 people with type 2 diabetes prescribed oral semaglutide, with a median age of 64 and a BMI of 33.8.[2]
- Overall urate fell 0.1 mg/dL at six months, which was not statistically significant (P = 0.52), and 0.2 mg/dL at twelve months (P = 0.01).
- In people who started above 6 mg/dL, reductions were larger: 0.6 and 0.8 mg/dL.
- The changes were independent of weight loss, of improved blood sugar control, and of prior GLP-1 or SGLT2 inhibitor use.
The trial put 72.7% of the urate drop down to weight loss. The real-world cohort found its smaller drop was independent of weight loss.
How both can be right
They are not the same experiment, and the differences are large enough to explain a lot without anyone being wrong.
| SURMOUNT-1 post hoc | URISEMA | |
|---|---|---|
| Design | Randomized, placebo-controlled | Retrospective, observational |
| Drug | Tirzepatide, injected | Oral semaglutide |
| Population | Obesity or overweight | Type 2 diabetes, median age 64 |
| Weight loss achieved | Up to 20.9% | Not the focus; much smaller |
| Baseline urate | Across all quartiles | Mostly already below target |
The last two rows do most of the work. If weight loss drives urate down, a trial producing 20% weight loss will show a large effect largely explained by weight, while a real-world cohort losing far less will show a small effect that weight cannot explain, because there was not enough weight change to explain it with. Two-thirds of the URISEMA cohort were already under the treatment target before starting.
That reading fits both studies but is established by neither: probably weight-driven at large weight losses, possibly something else at small ones, with no study yet designed to separate them.
What neither study did
So the supportable claim is narrow: these drugs lower serum uric acid, by an amount that depends heavily on how much weight comes off. Whether that translates into fewer gout attacks has only been checked indirectly. A 2024 pooled analysis of 22 randomized outcome trials of newer diabetes drugs found no significant effect of GLP-1 drugs on the risk of gout, while SGLT2 inhibitors lowered it.[3] That is a test of gout occurring in large trial populations, not of flares in people who already have gout, and the authors of the randomized uric-acid analysis still call for further investigation into a possible role in treating it. If aches rather than gout are the worry, what the trials counted for joint and back pain is covered separately. Whether a lower blood level means fewer uric acid kidney stones has not been tested; see GLP-1 drugs and kidney stones.
One further caution on URISEMA’s predictors. The two factors it identified (starting at or above 7 mg/dL, and switching from a DPP-4 inhibitor) carry odds ratios of 4.54 and 6.53 with intervals running to 19.25 and 27.32. In 236 retrospective patients, intervals that wide establish a direction and very little else.
Frequently Asked Questions
References
- 1.Sattar N, Scilletta S, Stefanski A, et al. Tirzepatide and change in uric acid and its association with weight reduction: post hoc analyses of the SURMOUNT-1 randomised placebo-controlled trial Annals of the Rheumatic Diseases. 2026. PMID: 41198460.
- 2.Moreno-Pérez O, Tejera-Muñoz A, Carreño-Valdivia R, et al. Impact of oral semaglutide on serum urate levels in people with type 2 diabetes: A retrospective real-world analysis (URISEMA study) Seminars in Arthritis and Rheumatism. 2025. PMID: 40816061.
- 3.Wang A, Shi W, Zhang N, et al. Newer Glucose-Lowering Drugs and Risk of Gout: A Network Meta-Analysis of Randomized Outcomes Trials Clinical Therapeutics. 2024. PMID: 38796335.
Compare the sellers
Related research
What These Hormones Do Without a Pancreas
To isolate what the gut hormones do outside the pancreas, researchers studied twelve people who no longer have one, and blocked the receptors. The one clear result was about bone.
6 min read
Taste Got Better, Not Worse
People on these drugs routinely say food tastes wrong. A trial measured taste objectively, biopsied participants' tongues and scanned their brains, and found taste recognition improved.
6 min read
The Fat Pads in Your Ears
Your eustachian tube is held closed partly by fatty cushions. Two cases describe it staying open after weight loss on a GLP-1, and the adverse event database records the symptom zero times.
6 min read
Is It Just the Weight Loss?
Every benefit reported for these drugs runs into the same question. A post hoc analysis of the SURMOUNT-OSA trials tried to separate the drug from the weight, and found the sleep apnea improvement doing work of its own.
7 min read
A Weight Drug for Having Too Little Fat
Lipodystrophy is the opposite of obesity: people are missing fat tissue, and are severely metabolically ill because of it. In a cohort given tirzepatide, those with familial partial lipodystrophy cut their daily insulin by a median of 109 units.
6 min read
Genetics Caused It, and the Drug Still Worked
MC4R mutations are the most common single genetic cause of obesity, and sit at the center of the brain's appetite pathway. Carriers in SURMOUNT-1 lost 18.3% of their weight against 19.9% in everyone else.
6 min read
Where to get GLP-1 online, safely: sellers our editors have checked
These are telehealth sellers our editors have checked. For each one we hold a price, the form the drug comes in, and the states it reaches.
No insurance needed · vetted by our editors
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
Embody
A flat compounded tirzepatide or semaglutide price at every dose, from a seller that names its pharmacies
From $79/mo
Get started →Bodybuilding Health+
Seeing what it charges before you answer any medical questions
From $179/mo
Get started →YourEra
Semaglutide at $99/month, well below the typical price
From $99/mo
Get started →